| 0.3691 0.009 (2.5%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.51 | 1-year : | 0.58 |
| Resists | First : | 0.44 | Second : | 0.49 |
| Pivot price | 0.38  |
|||
| Supports | First : | 0.35 | Second : | 0.29 |
| MAs | MA(5) : | 0.37 |
MA(20) : | 0.4 |
| MA(100) : | 0.44 |
MA(250) : | 4.42 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 11.9 |
D(3) : | 13.6 |
| RSI | RSI(14): 40.3 |
|||
| 52-week | High : | 12.47 | Low : | 0.34 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ THAR ] has closed above bottom band by 33.1%. Bollinger Bands are 85% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 89 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.37 - 0.37 | 0.37 - 0.37 |
| Low: | 0.35 - 0.36 | 0.36 - 0.36 |
| Close: | 0.37 - 0.37 | 0.37 - 0.37 |
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
Tue, 23 Apr 2024
Tharimmune Announces Option for Novel HER2/HER3 Cancer Therapies - Contract Pharma
Mon, 15 Apr 2024
Tharimmune forms advisory board to guide drug development - Investing.com
Mon, 01 Apr 2024
ThinkEquity initiates Tharimmune stock with a Buy By Investing.com - Investing.com
Mon, 11 Dec 2023
Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in ... - Yahoo Finance
Tue, 28 Nov 2023
Crude Oil Surges 2%; Tharimmune Shares Plummet - Cabaletta Bio (NASDAQ:CABA), Carbon Revolution (NASDAQ:C - Benzinga
Tue, 28 Nov 2023
Tharimmune (NASDAQ: THAR) up 46% one day, down 68% the next - Surprise! - Dhaka Tribune
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 1.1 (%) |
| Shares Short | 75 (K) |
| Shares Short P.Month | 76 (K) |
| EPS | -7.14 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.77 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -67.1 % |
| Return on Equity (ttm) | -127.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.06 |
| PEG Ratio | 0 |
| Price to Book value | 0.47 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.6 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|